China Biologic Products Holdings Profit Margin

China Biologic Products Holdings (CBPO) currently reports a profit margin of 29.04% as of December 2020. That compares with 27.22% in the prior-year period — up 6.7% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore China Biologic Products Holdings's profit margin history and peer comparisons.

China Biologic Products Holdings's profit margin increased from 27.22% to 29.04% — a 6.7% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Biologic Products Holdings's profit margin of 29.04% is higher than the Healthcare sector average of 13.89%. That is roughly 109.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but China Biologic Products Holdings's current 29.04% should be judged against Healthcare norms (sector average: 13.89%) and against CBPO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 29.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.